Anlotinib Plus Anti-PD-1 Antibody AK105 as Third or More-line Therapy for Advanced Pancreatic Cancer: a Prospective, Single-arm, Open-label, Pilot Study
Latest Information Update: 26 Jun 2023
At a glance
- Drugs Catequentinib (Primary) ; Penpulimab (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 18 Jun 2023 Planned End Date changed from 29 Feb 2024 to 29 Jun 2024.
- 18 Jun 2023 Planned primary completion date changed from 28 Feb 2023 to 28 Feb 2024.
- 18 Jun 2023 Status changed from not yet recruiting to recruiting.